WO1995024196A1 - New use of quinoline-3-carboxamide compounds - Google Patents

New use of quinoline-3-carboxamide compounds Download PDF

Info

Publication number
WO1995024196A1
WO1995024196A1 PCT/SE1995/000245 SE9500245W WO9524196A1 WO 1995024196 A1 WO1995024196 A1 WO 1995024196A1 SE 9500245 W SE9500245 W SE 9500245W WO 9524196 A1 WO9524196 A1 WO 9524196A1
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
quinoline
compound
bound
methyl
Prior art date
Application number
PCT/SE1995/000245
Other languages
French (fr)
Inventor
Bo Nilsson
Per GJÖRSTRUP
Agneta Svedberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to EE9600127A priority Critical patent/EE9600127A/en
Priority to AU20887/95A priority patent/AU679633B2/en
Priority to JP7523404A priority patent/JPH09510199A/en
Priority to EP95913458A priority patent/EP0749310A1/en
Priority to US08/704,587 priority patent/US5726183A/en
Publication of WO1995024196A1 publication Critical patent/WO1995024196A1/en
Priority to KR1019960704979A priority patent/KR970701546A/en
Priority to FI963531A priority patent/FI963531A0/en
Priority to NO963762A priority patent/NO963762D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Definitions

  • the present invention concerns the use of quinol ⁇ ne-3-carboxamide compounds, in particular roquinimex (Linomide ® ), or a pharmaceutically acceptable salt thereof for treating psoriasis or conditions associated with psoriasis.
  • roquinimex Linomide ®
  • a pharmaceutically acceptable salt thereof for treating psoriasis or conditions associated with psoriasis.
  • Psoriasis is a common disease which affects about 2 % of the population of Scandinavia.
  • Hereditary factors are important. If one parent has psoriasis, the risk for the child is 25% and if both parents have psoriasis there is a risk of 60 - 70%. Drugs thought to precipitate or worsen psoriasis include alcohol and, in some patients, ⁇ -blockers and non-steroidal anti-inflammatory agents.
  • Psoriasis is characterised by thickened, erythematous, well- demarcated areas of skin covered by silvery scales. The extent of involvement ranges from isolated, small lesions to the whole body surface. Nails are involved in up to 50 % of psoriasis patients. Because of the heterogenic nature of psoriasis, other papulosquamous dermatoses may need to be considered in the differential diagnosis. There are several clinical forms of psoriasis and it can change qualitatively from stable plaque lesions to an unstable form typified by eruptive inflammatory lesions.
  • Psoriatic arthritis is defined as "psoriasis (of skin or nails) associated with inflammatory arthritis (peripheral and/or spinal) and usually a negative seroiogical test for rhematoid factor". The incidence of arthritis in the psoriatic population is about 7 %.
  • psoriatic arthritis The clinical features of psoriatic arthritis are: (1 ) distal arthitis - an asymmetrical arthritis involving the terminalinterphalangeal joints of the hands and interphalangeal joints of the toes; there is invariably nail involvement; (2) artrophathy indistinguishable from rheumatoid arthritis, although milder; (3) a severe deforming type of arthristis (psoriatic arthritis mutilans), producing osteolysis of the hands and feet, usually associated with severe inflammatory forms of psoriasis; (4) an ankylosing spondylopathy; and (5) a mono-arthritis or oligo-arthritis.
  • Psoriasis is not a static disease: seasonal fluctuations, spontaneous remissions, and physical and emotional well-being all affects the disease
  • Methotrexate is indicated only for recalcitrant psoriasis, unresponsive to topical therapy.
  • the main side effects are acute marrow suppression and a long term risk of hepatic fibrosis and cirrhosis which is related to cumulative life time dosage and regimen employed.
  • Retinoid is a generic name that includes naturally occuring compounds with vitamin A activity and any synthetic analogues of retinol.
  • retonoid therapy is restricted to severe, recalcitrant psoriasis. It is especially valuable for initial treatment of the severe, inflammatory forms of the disease, that is erythrodermic or postular psoriasis, producing a more rapid response than methotrexate.
  • Cyklosporin is effective for severe psoriasis, and providing that guidelines for treatment are observed it also seems safe when used over periods of up to a year.
  • the long term safety af cyklosporin in patients with psoriasis is still to be established it is not the drug of choice for the patient likely to be require continous treatment for many years.
  • the main side effects are hypertension and renal impairment, both of which are reversible if guideines for treatment are followed.
  • the incidence of lymphoma is increased in people receiving cyklosporin long term.
  • Quinoline-3-carboxamide compounds have been suggested as phar ⁇ maceuticals.
  • the compounds have comprised the structure given in formula I below, optionally with substituents for the hydrogen atoms shown (H 1"9 , where H 9 is part of X, or X 2 as shown in (b) below) and, where appropriate, salts of the compounds.
  • This formula is a collective formula for the tautomeric structures ll-IV.
  • X 1 and X 2 are separately selected from an oxygen atom or an NH 9 group that possibly is substituted, said X, and X 2 being bound by a
  • H 1"9 are hydrogens, with the provision that H 9 is only present when at least one of X. and X 2 is the NH 9 group.
  • H 7 and H 8 are hydrogens that are attached to different atoms selec ⁇ ted among X.,, X 2 and the nitrogen atom in the quinoline ring said X, and X 2 being bound by a single bond to the ring when attached to H 7 or H 8 and by a double bond when not bound to H 7 or H 8 .
  • Patents and patent applications given above are hereby incorporated by reference. In general it can be stated that many of the compounds comprising structure I are classified as immune modulators with individual effects spanning the spectra from suppression to stimulation of the immune system. The specific effect achieved depends on the substituents.
  • One of the most important compounds with formula I are the 1,2- dihydro-hydroquinoline-3-carboxamides, particularly N-phenyl-N-methyl-1 ,2- dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide (roquinimex, trade mark Linomide ® ), i.e. structures I and II with a substituent for H 1 that equals phenyl, for H 2 that equals methyl, for H 8 that equals methyl (attached to the nitrogen atom of the quinoline ring), with no substituents for H 3"7 , with H 7 attached to X 1 ( and with each of X., and X 2 equaling an oxygen atom. .
  • the compound has double bonds between positions 3 and 4 and between position 2 and X 2 .
  • Published PCT-application WO 91/12804 discloses roquinimex as a drug for the treatment of retrovirus infections.
  • WO 91/14432 discloses roqui ⁇ nimex as a drug for regenerating lymphoid cells in patients treated with autologous bone marrow transplantation.
  • WO 93/06829 discloses roquini ⁇ mex as a drug for the treatment of multiple sclerosis.
  • JP 4041425 discloses 5-Lipoxygenase inhibitors containing 4- aminophenol derivatives or salts thereof which are claimed as remedies for i.a. psoriasis.
  • One such derivative is the amide of the 4-aminophenol derivative of 3-quinoline carboxylic acid.
  • This 3-quinoline carboxylic acid moiety anyhow completely lacks the characteristic substitution pattern which is essential for the compounds of the present invention.
  • Cyklosporin A which is a potent immune suppressor interfering with T cell reponse has shown to be effective in treating severe psoriasis.
  • Roquini ⁇ mex completely abolishes the immunosupressive effect of Cyklosporin in a heart allograft model.
  • Roquinimex may be used as such or as a pharmaceutically accep ⁇ table salt thereof. Furthermore, roquinimex can be used in combination with other agents. Formulations that could be used according to the present invention are disclosed in US patent No. 4,547,511 col. 11.
  • One major objective of the invention is to provide a method for treating psoriasis or conditions associated with psoriasis with quinoline-3- carboxamide compounds, in particular roquinimex (Linomide ® ), or a pharma- cologically acceptable salt thereof.
  • Patient No.10 His psoriasis engaged knees, capitillum, nails, eye lashes, hands and elbows. After six months of treatment with roquinimex he was completely recovered from his psoriasis. The patient was treated for a total of seventeen months. He received a partial remission of his renal cell carcinoma after seven months of treatment with a response duration of fifteen months. Six months after treatment withdrawal his psoriasis re ⁇ appeared, although to lesser extent than before.
  • Example 2 Patient No. 15: His psoriasis improved during treatment with roqui ⁇ nimex and he was completely recovered after seventeen months. His renal cancer stabilized during treatment and the treatment was terminated after two years due to progressive disease.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The use of an anti-psoriasis quinoline-3-carboxamide compound comprising the structure (I) above, optionally with substituents for the hydrogen atoms shown (H1-9), or a pharmacologically acceptable salt of said compound, where (a) -------- represents that there are two conjugated double bonds between the atoms comprised by the dashed line, (b) X¿1? and X2 are separately selected from an oxygen atom or an NH?9¿ group, said X¿1? and X2 being bound by a single bond to the ring when attached to H?7 or H8¿ and by a double bond when not bound to H?7 or H8, (c) H1-9¿ are hydrogens with the provision that H9 is only present when at least one of X¿1? and X2 is the NH?9¿ group, (d) H?7 and H8¿ are hydrogens that are attached to different atoms selected among X¿1?, X2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for treating psoriasis or conditions associated with psoriasis. Also described are methods for treating psoriasis or conditions associated with psoriasis in which methods the above compounds are administered to a living body. Particularly preferred compounds are N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or a salt thereof.

Description

NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS
The present invention concerns the use of quinolιne-3-carboxamide compounds, in particular roquinimex (Linomide®), or a pharmaceutically acceptable salt thereof for treating psoriasis or conditions associated with psoriasis.
Background of the invention
Psoriasis is a common disease which affects about 2 % of the population of Scandinavia.
Hereditary factors are important. If one parent has psoriasis, the risk for the child is 25% and if both parents have psoriasis there is a risk of 60 - 70%. Drugs thought to precipitate or worsen psoriasis include alcohol and, in some patients, β-blockers and non-steroidal anti-inflammatory agents.
Psoriasis is characterised by thickened, erythematous, well- demarcated areas of skin covered by silvery scales. The extent of involvement ranges from isolated, small lesions to the whole body surface. Nails are involved in up to 50 % of psoriasis patients. Because of the heterogenic nature of psoriasis, other papulosquamous dermatoses may need to be considered in the differential diagnosis. There are several clinical forms of psoriasis and it can change qualitatively from stable plaque lesions to an unstable form typified by eruptive inflammatory lesions.
Psoriatic arthritis is defined as "psoriasis (of skin or nails) associated with inflammatory arthritis (peripheral and/or spinal) and usually a negative seroiogical test for rhematoid factor". The incidence of arthritis in the psoriatic population is about 7 %. The clinical features of psoriatic arthritis are: (1 ) distal arthitis - an asymmetrical arthritis involving the terminalinterphalangeal joints of the hands and interphalangeal joints of the toes; there is invariably nail involvement; (2) artrophathy indistinguishable from rheumatoid arthritis, although milder; (3) a severe deforming type of arthristis (psoriatic arthritis mutilans), producing osteolysis of the hands and feet, usually associated with severe inflammatory forms of psoriasis; (4) an ankylosing spondylopathy; and (5) a mono-arthritis or oligo-arthritis.
Psoriasis is not a static disease: seasonal fluctuations, spontaneous remissions, and physical and emotional well-being all affects the disease
SUBSTITUTE SHEET and hence its management. Most patients with localised, plaque-type psoriasis are able to controll their disease at home with topical therapy with corticosteroid creams and ointments. For the more widespread forms, some form of phototherapy, either alone or combined with topical therapy, is usually needed. In resistant psoriasis, photochemotherapy or systemic therapy may be indicated.
Methotrexate is indicated only for recalcitrant psoriasis, unresponsive to topical therapy. The main side effects are acute marrow suppression and a long term risk of hepatic fibrosis and cirrhosis which is related to cumulative life time dosage and regimen employed. Retinoid is a generic name that includes naturally occuring compounds with vitamin A activity and any synthetic analogues of retinol. As with methotrexate, retonoid therapy is restricted to severe, recalcitrant psoriasis. It is especially valuable for initial treatment of the severe, inflammatory forms of the disease, that is erythrodermic or postular psoriasis, producing a more rapid response than methotrexate. Cyklosporin is effective for severe psoriasis, and providing that guidelines for treatment are observed it also seems safe when used over periods of up to a year. However, as the long term safety af cyklosporin in patients with psoriasis is still to be established it is not the drug of choice for the patient likely to be require continous treatment for many years. The main side effects are hypertension and renal impairment, both of which are reversible if guideines for treatment are followed. In other clinical conditions, such as immunosuppression after transplantation, the incidence of lymphoma is increased in people receiving cyklosporin long term.
Quinoline-3-carboxamide compounds have been suggested as phar¬ maceuticals. The compounds have comprised the structure given in formula I below, optionally with substituents for the hydrogen atoms shown (H1"9, where H9 is part of X, or X2 as shown in (b) below) and, where appropriate, salts of the compounds.
UBSTm m= SHEET
Figure imgf000005_0001
This formula is a collective formula for the tautomeric structures ll-IV.
Figure imgf000005_0002
( ID ( III )
Figure imgf000005_0003
( IV)
In formula l-IV:
(a) represents that there are two conjugated double bonds between the atoms comprised by the dashed line (only formula I).
(b) X1 and X2 are separately selected from an oxygen atom or an NH9 group that possibly is substituted, said X, and X2 being bound by a
SUBSTITUTE SHEET single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8. (c) H1"9 are hydrogens, with the provision that H9 is only present when at least one of X. and X2 is the NH9 group. (d) H7 and H8 are hydrogens that are attached to different atoms selec¬ ted among X.,, X2 and the nitrogen atom in the quinoline ring said X, and X2 being bound by a single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8. The substituents that are to replace H1"9 may, according to the prior art, comprise any substituent that gives compounds that can be isolated. See for instance Indian Journal of Chemistry Vol 17B (1979) 488-90 (anti- inflammatory properties), US 3,960,868 (=GB 1,467,061 , analgesic, anticon- ceptive, anti-inflammatory and anti-allergic properties), US 4,547,511 and 4,738,971 (enhancing cell-mediated immunity), WO 9015052 (= U.S. S.N. 651,234, filed May 31 , 1990) (immunomodulator), US 4,107,310 (analgetics) and JP 68023948 (bacteriocides). Patents and patent applications given above are hereby incorporated by reference. In general it can be stated that many of the compounds comprising structure I are classified as immune modulators with individual effects spanning the spectra from suppression to stimulation of the immune system. The specific effect achieved depends on the substituents.
One of the most important compounds with formula I are the 1,2- dihydro-hydroquinoline-3-carboxamides, particularly N-phenyl-N-methyl-1 ,2- dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide (roquinimex, trade mark Linomide®), i.e. structures I and II with a substituent for H1 that equals phenyl, for H2 that equals methyl, for H8 that equals methyl (attached to the nitrogen atom of the quinoline ring), with no substituents for H3"7, with H7 attached to X1 ( and with each of X., and X2 equaling an oxygen atom. . The compound has double bonds between positions 3 and 4 and between position 2 and X2.
The scientific experimentation with roquinimex has shown that roquinimex has multiple immunological activities. It has thus been found that roquinimex increases the proliferative response to T and B cell mito-
SUBSTITUTE SHEET gens [28], enhances antibody production [29] and augments NK cell activity [30, 31]. Moreover, its immunostimulating and immunoregulating properties may be useful in the treatment of tumors [32] and systemic lupus erythe- matosis [33, 34] as suggested in US Patents 4,547,511 and 4,738,971. Published PCT-application WO 91/12804 discloses roquinimex as a drug for the treatment of retrovirus infections. WO 91/14432 discloses roqui¬ nimex as a drug for regenerating lymphoid cells in patients treated with autologous bone marrow transplantation. WO 93/06829 discloses roquini¬ mex as a drug for the treatment of multiple sclerosis. These published patent applications are hereby incorporated by reference.
Quinoline-3-carboxamide compounds according to the present invention are hitherto not known for treating psoriasis. JP 4041425 (TANABE SEIYAKU CO) discloses 5-Lipoxygenase inhibitors containing 4- aminophenol derivatives or salts thereof which are claimed as remedies for i.a. psoriasis. One such derivative is the amide of the 4-aminophenol derivative of 3-quinoline carboxylic acid. This 3-quinoline carboxylic acid moiety anyhow completely lacks the characteristic substitution pattern which is essential for the compounds of the present invention. Summary of the invention According to the present invention it has now surprisingly been shown that treatment with quinoline-3-carboxamide compounds, in particular roquinimex (Linomide®), or a pharmaceutically acceptable salt thereof for treating psoriasis or conditions associated with psoriasis.
Cyklosporin A which is a potent immune suppressor interfering with T cell reponse has shown to be effective in treating severe psoriasis. Roquini¬ mex completely abolishes the immunosupressive effect of Cyklosporin in a heart allograft model.
Roquinimex may be used as such or as a pharmaceutically accep¬ table salt thereof. Furthermore, roquinimex can be used in combination with other agents. Formulations that could be used according to the present invention are disclosed in US patent No. 4,547,511 col. 11.
SUBSTITUTE 3HEET Objectives of the invention
One major objective of the invention is to provide a method for treating psoriasis or conditions associated with psoriasis with quinoline-3- carboxamide compounds, in particular roquinimex (Linomide®), or a pharma- cologically acceptable salt thereof.
Further objectives are to provide drugs to be used for the manufac¬ ture of pharmaceutical compositions for the treatment of the conditions given in the preceding sentence.
Other objectives of the invention will become apparent to one skilled in the art, and still other objectives will become apparent hereinafter.
Patient studies
Two patients with psoriasis have so far been subjected to long term treatement with roquinimex. The patients had advanced renal cell carcinoma and were treated with roquinimex in a phase ll-study (CTN: T89OL01) with a dose of 15 mg twice weekly.
Example 1
Patient No.10 : His psoriasis engaged knees, capitillum, nails, eye lashes, hands and elbows. After six months of treatment with roquinimex he was completely recovered from his psoriasis. The patient was treated for a total of seventeen months. He received a partial remission of his renal cell carcinoma after seven months of treatment with a response duration of fifteen months. Six months after treatment withdrawal his psoriasis re¬ appeared, although to lesser extent than before.
Example 2 Patient No. 15: His psoriasis improved during treatment with roqui¬ nimex and he was completely recovered after seventeen months. His renal cancer stabilized during treatment and the treatment was terminated after two years due to progressive disease.
None of the patients had any other concomitant therapy for their psoriasis.
SUBSTITUTE SHEET

Claims

CLAIMS 1. The use of an anti-psoriasis quinoline-3-carboxamide compound comprising structure I, optionally with substituents for the hydrogen atoms shown (H1"9), or a pharmaceutically acceptable salt of said compound
Figure imgf000009_0001
where
(a) represents that there are two conjugated double bonds between the atoms comprised by the dashed line,
(b) X, and X2 are separately selected from an oxygen atom or an NH9 group, said X, and X2 being bound by a single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8,
(c) H1"9 are hydrogens, with the provision that H9 is only present when at least one of X, and X2 is the NH9 group,
(d) H7 and H8 are hydrogens that are attached to different atoms selected among X„ X2 and the nitrogen atom in the quinoline ring, for the manufacture of a composition intended for treating psoriasis or conditions associated with psoriasis.
The use of an anti-psoriasis compound according to claim ^ c h a ¬ r a c t e r i z e d in that the compound is N-phenyl-N-methyl-1,2- dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide.
SUBSTITUTE SHEET Method for treating psoriais or conditions associated with psoriasis by administration of an effective amount of an anti-psoriasis quinoline-3- carboxamide compound or a pharmacologically acceptable salt thereof to a living body suffering from or being at risk for acquiring psoriasis or conditions associated with psoriasis , whereby said com¬ pound comprises the structure I, optionally with substituents for the hydrogen atoms shown (H1"9)
Figure imgf000010_0001
where (a) represents that there are two conjugated double bonds bonds between the atoms comprised by the dashed line,
(b) X, and X2 are separately selected from an oxygen atom or an NH9 group, said Xn and X2 being bound by a single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8,
(c) H1*9 are hydrogens, with the provision that H9 is only present when at least one of X, and X2 is NH9 group,
(d) H7 and H8 are hydrogens that are attached to different atoms selected among X X2 and the nitrogen atom (N) in the quino¬ line ring.
Method according to claim 3 wherein the compound is N-phenyl-N- methyl-1 ,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carbox- amide.
SUBSTITUTE SHEET 5. Method according to anyone of the preceding claims wherein the administration is oral.
6. Method according to anyone of the claims 1 - 4 wherein the admini- stration is by injection.
7. Method according to anyone of the claims 1 - 4 wherein the admini¬ stration is parenteral.
8. Method according to anyone of the preceding claims wherein the effective amount is from about 0,01 to about 10 mg/kg body weight, preferably from about 0,05 to about 1 mg/kg body weight, whereby said dose is administered from once daily to once a fortnight.
SUBSTITUTE SHEET
PCT/SE1995/000245 1994-03-10 1995-03-08 New use of quinoline-3-carboxamide compounds WO1995024196A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EE9600127A EE9600127A (en) 1994-03-10 1995-03-08 Use of quinoline-3-carboxamide compounds for new purposes
AU20887/95A AU679633B2 (en) 1994-03-10 1995-03-08 New use of quinoline-3-carboxamide compounds
JP7523404A JPH09510199A (en) 1994-03-10 1995-03-08 Novel use of quinoline-3-carboxamide compounds
EP95913458A EP0749310A1 (en) 1994-03-10 1995-03-08 New use of quinoline-3-carboxamide compounds
US08/704,587 US5726183A (en) 1994-03-10 1995-03-08 Use of quinoline-3-carboxamide compounds
KR1019960704979A KR970701546A (en) 1994-03-10 1996-09-09 NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS
FI963531A FI963531A0 (en) 1994-03-10 1996-09-09 New use of quinoline-3-carboxamide compounds
NO963762A NO963762D0 (en) 1994-03-10 1996-09-09 New use of quinoline-3-carboxamide compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400810A SE9400810D0 (en) 1994-03-10 1994-03-10 New use of quinoline-3-carboxamide compounds
SE9400810-9 1994-03-10

Publications (1)

Publication Number Publication Date
WO1995024196A1 true WO1995024196A1 (en) 1995-09-14

Family

ID=20393230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1995/000245 WO1995024196A1 (en) 1994-03-10 1995-03-08 New use of quinoline-3-carboxamide compounds

Country Status (11)

Country Link
US (1) US5726183A (en)
EP (1) EP0749310A1 (en)
JP (1) JPH09510199A (en)
KR (1) KR970701546A (en)
AU (1) AU679633B2 (en)
CA (1) CA2185135A1 (en)
EE (1) EE9600127A (en)
FI (1) FI963531A0 (en)
SE (1) SE9400810D0 (en)
WO (1) WO1995024196A1 (en)
ZA (1) ZA951966B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003991A1 (en) * 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
WO2000003992A1 (en) * 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (en) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
US8962598B2 (en) * 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960868A (en) * 1973-05-11 1976-06-01 Ciba-Geigy Corporation Derivatives of 6,7 or 8 cycloalkyl 4-oxo quinoline 3 carboxylic acid
US4107310A (en) * 1976-02-11 1978-08-15 Roussel Uclaf Quinoline-3-carboxamides
US4547511A (en) * 1981-03-03 1985-10-15 Aktiebolaget Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
WO1990015052A1 (en) * 1989-06-09 1990-12-13 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
WO1991012804A1 (en) * 1990-02-22 1991-09-05 Kabi Pharmacia Ab New use
WO1991014432A1 (en) * 1990-03-27 1991-10-03 Kabi Pharmacia Ab Supportive use
WO1992016104A1 (en) * 1991-03-13 1992-10-01 Smithkline Beecham Corporation Leukotriene antagonists
WO1993006829A1 (en) * 1991-10-09 1993-04-15 Kabi Pharmacia Ab New use of substituted quinoline carboxamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
JP3464731B2 (en) * 1995-07-03 2003-11-10 バブコック日立株式会社 Gas temperature measuring device having a light guide with black body film
JPH09114432A (en) * 1995-10-20 1997-05-02 Brother Ind Ltd Color conversion device
JPH09112804A (en) * 1995-10-23 1997-05-02 Ishikawajima Harima Heavy Ind Co Ltd Furnace wall structure of coal fired boiler
GB2308133B (en) * 1995-12-13 2000-06-21 Kennametal Inc Cutting tool for machining titanium and titanium alloys
JPH09204325A (en) * 1996-01-26 1997-08-05 Nec Telecom Syst Ltd File arrangement system for hard disk
JPH09207833A (en) * 1996-02-02 1997-08-12 Shin Caterpillar Mitsubishi Ltd Height adjusting device for crawler type vehicle
JPH09306829A (en) * 1996-05-16 1997-11-28 Sony Corp Scanning aligner and its method

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960868A (en) * 1973-05-11 1976-06-01 Ciba-Geigy Corporation Derivatives of 6,7 or 8 cycloalkyl 4-oxo quinoline 3 carboxylic acid
US4107310A (en) * 1976-02-11 1978-08-15 Roussel Uclaf Quinoline-3-carboxamides
US4547511A (en) * 1981-03-03 1985-10-15 Aktiebolaget Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
US4738971A (en) * 1981-03-03 1988-04-19 Aktiebolaset Leo N-aryl-1,2-dihydro-4-substituted-1-alkyl-2-oxo-quinoline-3-carboxamides
WO1990015052A1 (en) * 1989-06-09 1990-12-13 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
WO1991012804A1 (en) * 1990-02-22 1991-09-05 Kabi Pharmacia Ab New use
WO1991014432A1 (en) * 1990-03-27 1991-10-03 Kabi Pharmacia Ab Supportive use
WO1992016104A1 (en) * 1991-03-13 1992-10-01 Smithkline Beecham Corporation Leukotriene antagonists
WO1993006829A1 (en) * 1991-10-09 1993-04-15 Kabi Pharmacia Ab New use of substituted quinoline carboxamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 116, No. 23, 8 June 1992, (Columbus, Ohio, USA), page 85; abstract no. 228249n; & JP,A,04 041 425 (INOUE HIROZUMI et al.) 12 February 1992. *
INDIAN JOURNAL OF CHEMISTRY, Volume 17B, May 1979, D.R. SHRIDAR et al., "Anti-inflammatory Agents: Part II - Synthesis & Anti-inflammatory Activity of 3,4-Disubstituted 2-Oxo-1,2-dihydroquinolines". *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
WO2000003991A1 (en) * 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
WO2000003992A1 (en) * 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6593343B2 (en) 1998-07-15 2003-07-15 Active Biotech Ab Quinoline derivatives
US6605616B1 (en) 1998-07-15 2003-08-12 Active Biotech Ab Quinoline derivatives
CZ300229B6 (en) * 1998-07-15 2009-03-25 Active Biotech Ab Quinoline derivatives
HRP20010039B1 (en) * 1998-07-15 2009-04-30 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
US5726183A (en) 1998-03-10
AU2088795A (en) 1995-09-25
EP0749310A1 (en) 1996-12-27
JPH09510199A (en) 1997-10-14
FI963531A (en) 1996-09-09
CA2185135A1 (en) 1995-09-14
SE9400810D0 (en) 1994-03-10
KR970701546A (en) 1997-04-12
ZA951966B (en) 1995-12-11
FI963531A0 (en) 1996-09-09
EE9600127A (en) 1997-04-15
AU679633B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
US6492399B1 (en) Pharmaceutical compositions and methods for use
White Drug treatment and prevention of malaria
EP1086082B9 (en) Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
WO1996020599A1 (en) Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US6455554B1 (en) Oxopyridinyl pharmaceutical compositions and methods for use
US20060293289A1 (en) Compounds Capable of Activating Cholinergic Receptors
JP2002522390A (en) Pharmaceutical composition for prevention and treatment of central nervous system diseases
JP2003501416A (en) Pharmaceutical compositions and uses thereof
AU679633B2 (en) New use of quinoline-3-carboxamide compounds
US20040214835A1 (en) Compounds capable of activating cholinergic receptors
EP1857442A3 (en) Novel antimycobacterial compounds
JPH08503449A (en) Treatment agent for substance abuse disease
AU690661B2 (en) New use of quinoline-3-carboxamide compounds
US5162344A (en) Procaine double salt complexes
US7307092B2 (en) Compounds Capable of Activating Cholinergic Receptors
JP2002538207A (en) 3-Cyclopropylmethoxy-4-difluoromethoxy-N- (3,5-dichloropyrid-4-yl) benzamide for the treatment of multiple sclerosis
JPH02209808A (en) Treating method of matter addiction
US20100222395A1 (en) Compounds capable of activating cholinergic receptors
US20050282833A1 (en) Pharmacological treatment of psoriasis
GB2159410A (en) Cardioactive compounds
US5254686A (en) Procaine double salt complexes
AU2003236404B2 (en) Aryl substituted olefinic amines and their use as cholinergic receptors agonists
MXPA00012858A (en) Aryl substituted olefinic amines and their use as cholinergic receptors agonists
NL9500644A (en) Pharmaceutical preparation comprising fenoprofen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995913458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 282928

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2185135

Country of ref document: CA

Ref document number: 963531

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 08704587

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995913458

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995913458

Country of ref document: EP